Britain and America have forged a major commercial pact that will keep no levies on British pharmaceutical exports being sold in the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to boost expenditure on pharmaceuticals through the National Health Service (NHS). This commitment secures that duties on these vital products will remain at zero for a period of the next three years.
This deal follows previous threats to dramatically increase tariffs on branded pharmaceutical products, with figures mentioned up to 100%.
"This agreement with the UK reinforces the worldwide climate for new treatments and establishes much-needed balance to transatlantic medicine commerce," a release noted.
Trade Significance
Pharmaceuticals represent one of the Britain's biggest goods shipped to the America, which is by far the biggest buyer for leading British pharmaceutical firms.
Trade data indicate that in the year leading up to September, the UK shipped pharmaceutical products totaling billions to the US. This value represented a significant portion of British export trade in that span.
"This deal safeguards jobs, increases investment and sets the stage for the UK to establish itself as a worldwide center for medical research," a minister remarked.
Detailed British Pledges
The deal involves several specific commitments from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to double total NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at fifteen percent. In the past, rebates topped twenty percent.
Broader Context
The deal comes amid a protracted dispute between the drug companies and the UK government over spending levels and approval rates.
This friction were intensified by arguments that American patients were paying several times more for the same drugs than patients in the UK and Europe.
Recently, several significant drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar investments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS must spend more on treatments, noting that its spending on drugs had decreased as a share of its resources over the previous ten-year period.
